ImmunoGen, Inc. (IMGN) Receives Consensus Rating of “Hold” from Analysts

ImmunoGen, Inc. (NASDAQ:IMGN) has been assigned a consensus rating of “Hold” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.72.

Several equities analysts have recently weighed in on IMGN shares. William Blair restated an “outperform” rating on shares of ImmunoGen in a report on Monday, June 26th. Royal Bank Of Canada upgraded ImmunoGen from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $5.00 to $12.00 in a report on Thursday, July 6th. Leerink Swann upgraded ImmunoGen from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $3.53 to $3.90 in a report on Wednesday, April 19th. BidaskClub cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Zacks Investment Research cut ImmunoGen from a “hold” rating to a “sell” rating in a report on Monday, July 10th.

ImmunoGen (NASDAQ IMGN) traded up 0.572% during trading on Friday, reaching $6.155. The company had a trading volume of 1,401,143 shares. ImmunoGen has a 12 month low of $1.51 and a 12 month high of $8.04. The stock has a 50 day moving average price of $6.36 and a 200 day moving average price of $4.51. The firm’s market capitalization is $551.47 million.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The company had revenue of $39.02 million during the quarter, compared to the consensus estimate of $30.59 million. ImmunoGen’s revenue was up 426.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.53) EPS. On average, equities research analysts predict that ImmunoGen will post ($0.84) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2017/08/17/immunogen-inc-imgn-receives-consensus-rating-of-hold-from-analysts.html.

A number of large investors have recently modified their holdings of IMGN. Bank of Nova Scotia purchased a new stake in shares of ImmunoGen during the second quarter valued at about $591,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of ImmunoGen during the second quarter valued at about $126,000. Redmile Group LLC increased its stake in shares of ImmunoGen by 30.8% in the second quarter. Redmile Group LLC now owns 5,212,736 shares of the biotechnology company’s stock valued at $37,063,000 after buying an additional 1,228,002 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ImmunoGen during the second quarter valued at about $102,000. Finally, State Street Corp increased its stake in shares of ImmunoGen by 159.1% in the second quarter. State Street Corp now owns 4,141,583 shares of the biotechnology company’s stock valued at $29,450,000 after buying an additional 2,542,876 shares during the period. Institutional investors and hedge funds own 74.69% of the company’s stock.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply